Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy

J Korean Med Sci. 2008 Aug;23(4):737-9. doi: 10.3346/jkms.2008.23.4.737.

Abstract

The combination of atazanavir (ATV) and lopinavir/ritonavir (LPV/RTV) with nucleoside reverse transcriptase inhibitors (NRTI) has been used as a salvage regimen for human immunodeficiency virus (HIV)-positive patients. In this paper, we discuss two cases of HIV-positive patients who had long histories of virological failure following a heavy treatment of antiretroviral drugs, but then achieved virological suppression with double-boosted protease inhibitor (PI) regimens. In patients with multiple genotypic resistance to PIs and NRTIs, virological suppression can be achieved with a combination of ATV plus LPV/RTV with an NRTI backbone. The two cases in this report suggest that a combination of ATV plus LPV/RTV could be a useful salvage regimen for the subset of HIV-positive patients with limited treatment options.

MeSH terms

  • Adult
  • Atazanavir Sulfate
  • Drug Resistance, Multiple, Viral
  • Drug Therapy, Combination
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / administration & dosage*
  • Humans
  • Lopinavir
  • Male
  • Oligopeptides / administration & dosage*
  • Pyridines / administration & dosage*
  • Pyrimidinones / administration & dosage*
  • Ritonavir / administration & dosage*

Substances

  • HIV Protease Inhibitors
  • Oligopeptides
  • Pyridines
  • Pyrimidinones
  • Lopinavir
  • Atazanavir Sulfate
  • Ritonavir